Dr Ari Melnick has been appointed the new Director of the Josep Carreras Leukaemia Research Institute by the Board of Trustees. The institute specialises in biomedical research and precision medicine in the field of leukaemia and other hematologic malignancies.
Nuclear medicine (NM), one of the more mature technologies of diagnostic imaging, has been experiencing a rebirth in innovation and interest. The increasing prevalence of cancer, in part the result of improved diagnostic tests, an aging global population, and greater longevity, has created a robust demand for nuclear medicine. At the European Congress of Radiology (ECR) in Vienna, presenters…
A new method to quickly and accurately analyze the structure of collagen in tissue shows promise to improve the diagnostics of cancer and other diseases.
Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response to neoadjuvant chemotherapy and standard radiotherapy, new research finds.
Researchers discovered a key mechanism by which melanomas and other aggressive tumours prevent the immune system from detecting and attacking them – one of the greatest challenges in oncology today.
Cryoablation, the destruction of malignant cancer cells by freezing them, is increasingly becoming an alternative to having conventional lumpectomy for patients diagnosed with early-stage, localised, low-risk breast cancer. Findings from numerous recent clinical trials show that cancer recurrence rates are very low and are comparable to breast conservation surgery (BCS).
For patients, a liquid biopsy which checks for circulating tumour DNA of colon cancer, resembles a standard blood test. However, the method helps avoid chemotherapy for many, a new study finds.
A new study reveals that AI can accurately rule out negative low-dose CT (LDCT) scans, potentially reducing the workload of radiologists in lung cancer screening by up to 79%.
Late-stage breast cancer patients are more often affected by brain metastases than previously believed, a new study finds. The researchers suggest that MRI screening guidelines should reflect this.
Infection with the human papillomavirus (HPV) is the most common cause for cervical cancers. Now, researchers have developed a promising therapeutic vaccine against precancerous lesions.
Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could reduce wait times.
A new personalised oncology platform has been tested to detect circulating tumour DNA (ctDNA) in patients with lung adenocarcinoma before surgery, to predict their risk of cancer relapse.
Paediatric brain tumours are difficult to diagnose and treat – especially, when delays occur. A new study explored the impact of the Covid-19 pandemic on children with brain tumours.
Ovarian cancer is common and often only detected by chance. A newly developed AI-based model could help differentiate between benign and malignant ovarian lesions.
Complex diseases could require complex biomarkers for accurate diagnosis in the years ahead, according to a leading pathologist. In a keynote address to the 36th European Congress of Pathology in Florence, Italy, Professor Manuel Salto-Tellez highlighted this as one of the major future challenges for the discipline. However, he also believes pathologists will sit at the core of modern medicine.
Research offers new insights into harnessing the immune system to combat ovarian cancer. The findings could lead to personalized therapies that target the right patients at the right time.
Royal Philips announced a major advance in radiation oncology with 510(k) clearance from the US Food and Drug Administration (FDA) for its new detector-based spectral CT radiotherapy solution.
“There’s nothing else we can do”, “Why did you wait so long to come?” – doctors should avoid using such phrases. A new study points out the destructive potential of “never words”.
STAb-T, a new form of immunotherapy to treat solid tumours shows therapeutic potential in animal models with non-small cell lung cancer. The new strategy is designed to strengthen the defensive cells.
